The key data from the 2022 European Thyroid Association congress: Toward personalized treatment of Graves' orbitopathy

Ann Endocrinol (Paris). 2023 Dec;84(6):756-757. doi: 10.1016/j.ando.2023.05.007. Epub 2023 Jun 5.

Authors

Juliette Abeillon-du Payrat¹, Philippe Caron²

Affiliations

¹ Endocrinology and Metabolic Diseases Federation, Louis-Pradel Cardiovascular Hospital, Bron, France.
² Department of Endocrinology and Metabolic Diseases, Cardiovascular and Metabolic Unit, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.

PMID: 37285956
DOI: 10.1016/j.ando.2023.05.007

No abstract available

Keywords: Corticosteroids; Graves’ orbitopathy; Personalized treatment; Rituximab; Teprotumumab; Tocilizumab.

Publication types

Letter

MeSH terms

Glucocorticoids
Graves Ophthalmopathy* / therapy
Humans
Precision Medicine
Rituximab

Substances

Rituximab
Glucocorticoids